Boston-based food and beverage company Motif FoodWorks has secured $27 million in Series A funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced on August 15.

According to its Crunchbase profile, "Motif makes ingredients for the next generation of plant-based and healthy foods. We use fermentation to brew vital proteins and nutrients that power your body and please your palate. They are collaborating with chefs, health experts and food visionaries to create new building blocks for tomorrow’s food revolution."

The one-year-old startup also raised a $90 million Series A round earlier this year.

The round brings total funding raised by Boston companies in biotechnology over the past month to $75 million, an increase of $5.5 million from the month before. The local biotechnology industry has seen 41 funding rounds over the past year, securing a total of $1 billion in venture funding.

In other local funding news, hospitality and fitness company Biena Snacks announced an $8 million Series B funding round on August 14, financed by MAW Investments.

According to Crunchbase, "They have a line of all-natural roasted chickpea snacks in four different flavors. High protein, high fiber, delicious taste, perfect crunch."

Founded in 2012, the company has raised two previous rounds, including a $2.3 million Series A round in 2018.

Meanwhile, software company UptimeHealth raised $1 million in seed funding, announced on August 1. The round's investors were led by 2enable Partners.

From the company's Crunchbase profile, "We are professionals with medical device management backgrounds. We understand that inventory management, equipment maintenance and extra contracted services are a pertinent part of healthcare. When equipment goes down it can disrupt workflow, reduce the bottom line and negatively affect patient care."

UptimeHealth last raised $565,000 in angel funding earlier this year.

---

This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.